IL-15 Superagonist with or without Vaccine for Recurrent Prostate Cancer
This study is looking into new ways to treat prostate cancer that has come back after previous radiation therapy (biochemically recurrent prostate cancer). Researchers want to see if a drug called N-803, either alone or combined with a vaccine called ETBX-071, can help lower prostate-specific antigen (PSA) levels. PSA is a protein in the blood that can indicate prostate cancer. The study is open to men aged 18 and older who have a confirmed diagnosis of prostate adenocarcinoma and have previously received stereotactic body radiation therapy (SBRT). The main goal is to measure how well N-803, with or without the vaccine, works to reduce PSA levels over time. This treatment aims to boost your body's immune system to fight the cancer.
- Study design
- This is an interventional study with a planned enrollment of 65 participants. The phase of the study is not specified, and its current status is unclear.
- What's involved
- You would receive N-803 and/or ETBX-071 subcutaneously (under the skin) on Day 1 of every 3-week cycle for up to 8 cycles. You will also have a single intravenous (IV) injection of 18F-DCFPyL for imaging.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your PSA levels will be measured at the start of each treatment cycle, at the end of treatment, and every 4-8 weeks during follow-up for up to 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07686380
IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy
Not Yet Recruiting
PHASE2Ages 18+InterventionalTreatmentNational Cancer Institute (NCI)Government-funded
~65 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:N-803ETBX-71 Vaccine18F-DCFPyL
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Efficacy of N-803 alone or with ETBX-071 vaccine
Measured over D1 of each cycle of immunotherapy, at the end of treatment and every 4-8 weeks during follow-up until up to 5 years
Conditions
Where it's being run
1 sites across 1 statesMaryland1
Study leadership
- Melissa L Abel, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histopathological confirmation of prostate adenocarcinoma by the Laboratory of Pathology at the National Institutes of Health (NIH) Clinical Center prior to the study treatment initiation. If no pathologic specimen is available, participants may enroll with a pathologist s report showing a histologic diagnosis of prostate adenocarcinoma and a clinical course consistent with the disease from any outside site.
Biochemically recurrent prostate cancer, defined as PSA over 0.8 ng/ml following radical prostatectomy or \>= 2 ng/ml above the nadir following definitive radiotherapy or definitive radiotherapy (including brachytherapy) for localized prostate cancer.
Participants must be at least 1 year removed from definitive local therapy before the study treatment initiation.
Recovery to baseline from acute toxicity related to prior therapy, including surgery and radiation.
Hepatic function eligibility parameters: Bilirubin (total and direct) \<= upper limit of normal (ULN) (OR in participants with Gilbert s syndrome, a total bilirubin \<= 3.0), aspartate transaminase (AST) and alanine transaminase (ALT) \<= 1.5 times upper limit of normal.
Adequate renal function defined by a calculated creatinine clearance \> 50 mL/min according to the Cockcroft-Gault formula or by measure of creatinine clearance from 24-hour urine collection.
ECOG performance score 0-1.
No other active malignancies within the 36 months prior to the study treatment initiation (with the exception of nonmelanoma skin cancers or carcinoma in situ of the bladder).
18 years of age or older.
Individuals must agree to use effective contraception (barrier, vasectomy and/or abstinence) for the duration of study therapy and for four months after the last treatment administration. Individuals with partners with birthing potential will be recommended that their partner use a highly effective contraception (includes use of oral, injected or implanted hormonal methods of contraception, placement of certain intrauterine devices (IUD) or intrauterine systems (IUS), hysterectomy, oophorectomy, salpingectomy.
Individuals must agree to not donate sperm during the restricted period (for the duration of study therapy and for four months after the last dose of study treatment).
Negative CT scan/ Magnetic resonance imaging (MRI) for evidence of soft tissue metastasis (visceral or lymph node).
Negative Tc99 for evidence of bone disease.
Participants must have had prior SBRT to PSMA+ findings beyond the prostate and have had a documented 25% or more PSA rise from post-SBRT nadir
Baseline testosterone \>= 100 ng/dl.
Hematological parameters:
Granulocyte count \>= 1000/mm\^3
Platelet count \>= 100000/mm\^3
Hemoglobin (Hgb) \>= 10 g/dL
Participants must be able to understand and willing to sign a written informed consent document.
Exclusion
Immunocompromised status due to:
Human immunodeficiency virus (HIV) seropositivity
HBV or HCV seropositivity
Other immunodeficiency diseases
Active autoimmune diseases such as Addison's disease, Hashimoto's thyroiditis, systemic lupus erythematosus, Sjogren syndrome, scleroderma, myasthenia gravis, Goodpasture syndrome or active Grave's disease. Participants with a history of autoimmunity that has not required systemic immunosuppressive therapy or does not threaten vital organ function including central nervous system (CNS), heart, lungs, kidneys, skin, and gastrointestinal (GI) tract will be allowed. Participants with diabetes type I, vitiligo, or alopecia are allowed.
Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (e.g., corneal transplant, hair transplant).
Chronic administration (defined as daily or every other day for continued use \> 14 days) of systemic corticosteroids within 28 days before the study treatment initiation. Note: Use of corticosteroids with minimal systemic absorption (e.g., inhaled steroids, nasal sprays, and topical agents) is allowed.
Other medications used for urinary symptoms including 5-alpha reductase inhibitors (finasteride and dutasteride) and alternative medications known to alter PSA (e.g., phytoestrogens and saw palmetto) within 28 days prior to the study treatment initiation.
Major surgery within 28 days prior to study treatment initiation.
Systemic therapy, including any investigational therapy within 28 days prior to the study treatment initiation.
Radiation therapy within 14 days prior to the study treatment initiation.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drugs.
Clinically significant cardiovascular/cerebrovascular disease as follows: cerebral vascular accident/stroke (\< 6 months prior to the first planned dose of study drugs), myocardial infarction (\< 6 months prior to the first planned dose of study drugs), or any of the following at time of enrollment: unstable angina, congestive heart failure (New York Heart Association Classification Class \>= II), serious cardiac arrhythmia, or uncontrolled hypertension (SBP\>170/ DBP\>105).
Serious intercurrent medical illness evaluated by medical history and physical exam that would interfere with participant's ability to carry out the treatment program.
What this trial measures
- Efficacy of N-803 alone or with ETBX-071 vaccineD1 of each cycle of immunotherapy, at the end of treatment and every 4-8 weeks during follow-up until up to 5 years
PSA30 response- defined as a \>= 30% reduction in PSA from PSA at C1D1 of immunotherapy (comparing C1D1 PSA to timepoints during and after immunotherapy). The fractions with PSA30 response will be reported along with a 95% confidence interval, separately for the two randomized treatment groups.